A group of scientists from Monash University and King’s College London has developed a database of information that may help researchers find the link between type 2 diabetes and the coronavirus. The group designed the database for the following reasons: first, the increasing evidence that suggests that the coronavirus can actually cause individuals to become diabetic, and second, when compared to the general population, individuals who have type 2 diabetes are more likely to experience serious coronavirus symptoms and to die from the disease. Type 2 diabetes is a chronic condition that impacts the way the body processes blood sugar.
The database, dubbed the COVIDIAB registry, has been created to assist medical researchers to understand the association between diabetes and the coronavirus. The data that was gathered from patients included whether the diagnoses were new onset. The researchers suggest that the amount of data will increase as researchers learn more about the effect of the coronavirus on patients of diabetes. A couple of media outlets have revealed that the platform already has information from 350 doctors.
It still isn’t clear if the coronavirus does actually cause diabetes and neither is it clear why individuals who have diabetes experience more severe symptoms when they contract the coronavirus. Since the pandemic began, doctors have made reports that patients developed diabetes shortly after getting infected with the coronavirus.
Researchers are hopeful that the database would assist them in finding out if the complications caused by the coronavirus can bring about the onset of diabetes. Physicians will also need to know whether these coronavirus patients were prediabetic and the coronavirus infection triggered the disease, if they were going to develop diabetes in the future anyway, or if it is possible for individuals who have no propensity to becoming diabetic to develop the ailment soon after contracting the coronavirus.
Additionally, some researchers also revealed that there are two potential ways that the coronavirus could cause an individual to develop type 2 diabetes. The first way could occur as the coronavirus triggers an inflammatory reaction in an individual’s body, which affects blood sugar regulation because of the stress hormones that are released. The second way is when the pancreas is attacked, which leads to a decrease in the organ’s ability to produce and regulate levels of insulin in an individual’s body.
Researchers have also claimed that it is possible that some individuals may have developed diabetes after having steroids administered to them as part of their coronavirus treatment. The study will clarify all these issues.
Just as the team studying the link between the coronavirus and type 2 diabetes is relying heavily on data, so are many companies focusing harnessing the power of artificial intelligence and data analytics. A vivid illustration of this is RYAH Group Inc. which is tapping data analytics and IoT to develop products and software to make telehealth widely available, especially in the post-pandemic period.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. are available in the company’s newsroom at https://ibn.fm/RYAH
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Doctors in Spain recently handled a fascinating yet terrifying case of a patient that developed brain cancer-like symptoms and…
While immunotherapy is revolutionizing cancer therapy, response rates to these novel treatments are low and some patients…
Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production…
The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage…
As July came to an end, the United States reached an undesirable milestone: exceeding the…
Scientists and public health experts are warning that climate change is accelerating the rate at which infectious…